IDO1 and neoplasm: Importantly, this first publication utilizing AT-0174, showed efficacy in preclinical models of non–small cell lung cancer, inhibiting chemoresistant tumor growth, compared with single inhibition of IDO1, supporting that TDO2 or dual inhibition is necessary for a robust antitumor response (21).